|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 11
Zeitschriftenartikel
Erickson, Nicole; Schinkoethe, T.; Eckhardt, C.; Storck, L.; Joos, A.; Liu, L.; Ballmer, P. E.; Mumm, F.; Fey, T. und Heinemann, V.
(2021):
Patient-reported outcome measures obtained via E-Health tools ease the assessment burden and encourage patient participation in cancer care (PaCC Study).
In: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Bd. 29, Nr. 12: S. 7715-7724
[PDF, 768kB]
Jäger, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Winkler, E. und Heussner, P.
(2017):
Patients' preferences concerning their information needs and their preferred role in participation in end-of-life decision-making (EPAL-Study).
In: Oncology Research and Treatment, Bd. 40: S. 281-282
Mehlis, K.; Jaeger, E.; Laryionava, K.; Mumm, F.; Hiddemann, W.; Heussner, P. und Winkler, E. C.
(2016):
Importance of a good patient-communication in situations of treatment limitation - results from the EPAL-Study (Ethics Policy for Advanced Care Planning and Limiting Treatment).
In: Oncology Research and Treatment, Bd. 39: S. 302-303
Jaeger, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Winkler, E. C. und Heussner, P.
(2016):
Patients' preferences concerning quality and quantity of life. Results from the EPAL-Study (Ethics Policy for Advanced Care Planning and Limiting Treatment).
In: Oncology Research and Treatment, Bd. 39: S. 303
Mehlis, K.; Jaeger, E.; Laryionava, K.; Mumm, F.; Hiddemann, W.; Heussner, P. und Winkler, E. C.
(2016):
Patients' information needs and involvement in decisions to limit treatment in the EPAL-Study (Ethics policy for advanced care planning and limiting treatment).
In: Oncology Research and Treatment, Bd. 39: S. 303
Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zoellner, A.-K.; Koehnke, T.; Buecklein, V. L.; Mumm, F.; Haebe, S.; Witkowski, L.; Ledderose, G.; Stemmler, H.-J.; Spiekermann, K.; Hiddemann, W.; Hausmann, A. und Tischer, J.
(2016):
Sequential therapy in the setting of HLA-haploidentical transplantation utilizing T-cell-replete grafts and post-transplantation high-dose cyclophosphamide in the treatment of relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome.
In: Bone Marrow Transplantation, Bd. 51:
S29-S30
Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zoellner, A.-K.; Köhnke, T.; Engel, N.; Bücklein, V. L.; Schulz, C.; Mumm, F.; Berking, S.; Ledderose, G.; Stemmler, H.-J.; Spiekermann, K.; Hiddemann, W.; Hausmann, A. und Tischer, J.
(2016):
Results of sequential therapy in the setting of unmanipulated HLA-haploidentical transplantation utilizing post-transplantation high-dose cyclophosphamide in the treatment of high-risk AML and MDS.
In: Oncology Research and Treatment, Bd. 39: S. 77-78
Hilgendorf, I; Pulewka, K.; Herzberg, P. Y.; Greinix, H.; Heußner, P.; Mumm, F.; Harsdorf, S. von; Rieger, K.; Hemmati, P.; Holler, E.; Hochhaus, A. und Wolff, D.
(2016):
Adolescent and young adults versus older adults in the setting of allogeneic stem cell transplantation - two cohorts with special needs.
In: Oncology Research and Treatment, Bd. 39: S. 230-231
Jaeger, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Winkler, E. C. und Heußner, P.
(2016):
Development and Validity of a Checklist Assessing the Risk of Bias of Randomized Trials, Observational Studies and Systematic Reviews Analyzing Drug Adverse Events.
In: Oncology Research and Treatment, Bd. 39: S. 241
Jaeger, E.; Winkler, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W. und Heußner, P.
(2016):
End-of-Life decision-making in patients with advanced cancer - an ethics policy for advanced care planning and limiting treatment (EPAL).
In: Oncology Research and Treatment, Bd. 39: S. 31-32
Mehlis, K.; Jaeger, E.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Heußner, P. und Winkler, E. C.
(2016):
Patient information needs and treatment goals in the EPAL-Study (Ethics policy for advanced care planning and limiting treatment).
In: Oncology Research and Treatment, Bd. 39: S. 31